FDA DEVICE FACTS
NuVasive® VuePoint® II OCT System
Nu Vasive, Incorporated
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The NuVasive® VuePoint® II OCT System is intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion for th e following acute and chronic instabilities of the craniocervical junction, the cervical spin e (C1 to C7) and the thoracic spine (T1-T3): traumatic spinal fractures and/or traumatic disl ocations; instability or deformity; failed previous fusions (e.g., pseudoarthrosis); tum ors involving the cervical spine; and degenerative disease, including intractable radiculo pathy and/or myelopathy, neck and/or arm pain of discogenic origin as confirmed by radio graphic studies, and degenerative disease of the facets with instability. The VuePoint II OCT System i s a l s o intended to restore the integrity of the spinal column even in the absence of fusion for a limited time period in patients with advanced stage tumors invo lving the cervical spine in whom life expectancy is of insufficient duration to permit achievement of fusion. In order to achieve additional levels of fixation, the VuePoint II OCT System m a y b e connected to the NuVasive® SpheRx® Spinal System, Precept® Spinal System, Armada® Spinal System, Reline® System and Reline® 4.5-5.0 System via the rod to rod connectors or transition rods.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。